Welcome to our dedicated page for Leap Therapeutic news (Ticker: LPTX), a resource for investors and traders seeking the latest updates and insights on Leap Therapeutic stock.
The news feed for Leap Therapeutics, Inc. (historically Nasdaq: LPTX) captures the company’s transition from a biotechnology issuer focused on targeted and immuno-oncology therapeutics to the renamed Cypherpunk Technologies Inc. with an added digital asset treasury strategy. Press releases describe how the public company changed its name to Cypherpunk Technologies Inc., plans to trade under the ticker CYPH, and intends to acquire and hold Zcash (ZEC) while continuing cancer drug development through a subsidiary that will take the Leap Therapeutics name.
News items cover clinical and preclinical updates for the oncology pipeline, including detailed results from the randomized Phase 2 DeFianCe study of sirexatamab (DKN-01) plus bevacizumab and chemotherapy in microsatellite stable colorectal cancer, and preclinical findings for FL-501, a GDF-15–targeting monoclonal antibody associated with cancer cachexia research. Releases describe statistically significant benefits in DKK1-high colorectal cancer subgroups and activity of FL-501 in animal models of cachexia and chemotherapy-induced weight loss.
Investors can also follow strategic and corporate developments such as the initiation of a process to explore strategic alternatives for sirexatamab and FL-501, workforce reductions and restructuring to conserve cash, and the closing of a private placement led by Winklevoss Capital to fund the digital asset treasury strategy. Additional news highlights governance changes, including new board appointments linked to the financing, and the company’s rationale for focusing on Zcash as a privacy-preserving digital asset.
This page brings together these oncology, digital asset, financing, and governance announcements so readers can review how the historical LPTX issuer evolved into Cypherpunk Technologies Inc. and how its cancer programs and Zcash-focused treasury strategy are described in official communications.
Leap Therapeutics, Inc. (Nasdaq: LPTX) announced its participation in the European Society for Medical Oncology (ESMO) Congress from September 16-21, 2021. The company will present initial findings from the DisTinGuish Phase 2a study, evaluating DKN-01, an anti-DKK1 antibody, combined with tislelizumab in treating gastric or gastroesophageal junction cancer. A conference call is scheduled for September 16, 2021, to discuss these results. The study, involving 25 patients, aims to improve treatment responses in G/GEJ cancer.
Leap Therapeutics (Nasdaq: LPTX) announced that its CEO, Douglas E. Onsi, will present a corporate overview at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on July 14, 2021, at 1:00 p.m. ET. The presentation will be available live and as a replay on the company's Investors page.
Leap focuses on targeted and immuno-oncology therapeutics, with its lead candidate, DKN-01, in trials for various cancers. The company has a partnership with BeiGene for DKN-01 development in Asia and oceania.
Leap Therapeutics (Nasdaq: LPTX) announced that Douglas E. Onsi, CEO, will present a corporate overview at the Raymond James 2021 Virtual Human Health Innovation Conference on June 21, 2021, at 1:20 p.m. ET. The presentation will be accessible via the company's Investors page, with a replay available later. Leap is focused on developing immuno-oncology therapeutics, with DKN-01 as its leading candidate targeting DKK1 in various cancer types. The company has partnered with BeiGene for DKN-01 development in several regions excluding Japan.
Leap Therapeutics, Inc. (Nasdaq:LPTX) reported a net loss of $9.1 million for Q1 2021, up from $7.2 million in Q1 2020. The increase was driven by heightened development activities for its DKN-01 program and expanded headcount. License revenues remained steady at $0.4 million. R&D expenses rose to $6.8 million, reflecting more clinical trial costs and staffing. Leap completed enrollment in the DisTinGuish study, evaluating DKN-01 in gastric cancer, and presented promising data on DKN-01's efficacy in gynecological malignancies. Cash reserves stood at $43.5 million as of March 31, 2021.
Leap Therapeutics (Nasdaq: LPTX) and Flagship Biosciences have developed an innovative image analysis RNAscope assay for prospective patient enrollment in clinical trials. This assay, validated in a recent publication, aims to identify patients likely to benefit from the DKN-01 therapy for gastric and gastroesophageal junction adenocarcinoma. The collaboration enhances clinical development through improved screening accuracy and efficiency, utilizing digital analysis to minimize manual errors. The DKN-01 antibody targets the DKK1 protein, linked to poor patient prognosis.
Leap Therapeutics (LPTX) has partnered with Flagship Biosciences to utilize a clinically validated DKK1 RNAscope assay for patient enrollment in their clinical trials. This assay aims to identify patients with high DKK1 levels in gastric cancers for treatment with DKN-01 and tislelizumab. Results presented at the AACR Annual Meeting 2021 confirm the assay's specificity and sensitivity, adhering to CLIA guidelines. The partnership underscores Leap's clinical development strategy, facilitating rapid patient screening and enhancing trial enrollment efficiency.
Leap Therapeutics (Nasdaq:LPTX) announced the completion of enrollment for the first-line patient cohort in the DisTinGuish study, evaluating DKN-01, an anti-Dickkopf-1 antibody, combined with tislelizumab for treating gastric or gastroesophageal junction cancer. The Phase 2a trial will enroll up to 72 patients and aims to address a significant unmet medical need. Initial data is expected in the second half of 2021. DKN-01 has received Orphan Drug and Fast Track Designations from the FDA, highlighting its potential in combating this deadly cancer.
Leap Therapeutics (Nasdaq:LPTX) presented promising clinical data from its Phase 2 trial of DKN-01 during the Society of Gynecologic Oncology 2021 Annual Meeting. The study showcased DKN-01's effectiveness as a monotherapy and in combination with paclitaxel for patients with advanced gynecological cancers. Key findings revealed a complete response lasting over 2.5 years and improved outcomes for patients with DKK1-high tumors. Enhanced efficacy was noted in endometrioid histology patients. Leap is encouraged to further explore DKN-01, highlighting its tolerability and potential for improved survival rates.
Leap Therapeutics (Nasdaq:LPTX) reported its financial results for 2020, revealing a net loss of $27.5 million, down from $32.9 million in 2019, primarily due to reduced R&D expenses. The company secured a $51.75 million public offering and signed a licensing agreement with BeiGene for DKN-01 in key Asia-Pacific regions. Key advancements include positive outcomes in EGC cancer for DKN-01 and receiving both Orphan Drug and Fast Track Designations from the FDA. Cash and equivalents stood at $52.1 million as of December 31, 2020, signaling a stable financial position for ongoing projects.
Leap Therapeutics, Inc. (Nasdaq:LPTX) announced that its CEO, Douglas E. Onsi, will present a corporate overview at two upcoming virtual investor conferences. The first is the Raymond James 42nd Annual Institutional Investors Conference on March 1, 2021 at 10 a.m. Eastern Time. The second is the H.C. Wainwright Global Life Sciences Conference from March 9-10, 2021, with a presentation available at 7:00 a.m. Eastern Time on March 9. Leap focuses on developing targeted and immuno-oncology therapeutics, with its leading candidate, DKN-01, in clinical trials for various cancers.